Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind nivolumab vs dacarbazine in untreated unresectable or metastatic melanoma
2012-003718-16Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nivolumab in melanoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Overall survival. Started Nov 2012; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2012-003718-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003718-16.